<DOC>
	<DOC>NCT00455364</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.</brief_summary>
	<brief_title>Voriconazole as Prophylactic Therapy in Lung Transplant Recipients</brief_title>
	<detailed_description>All participants will receive itraconazole during their inpatient post transplant stay. As an outpatient, ten subjects will be randomized to receive itraconazole 200mg orally once daily for 6 month and ten patients to receive voriconazole 200mg orally twice daily for 6 months . All subjects will be followed in the clinic as per the standard transplant treatment</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Bilaterallung or singlelung transplant recipients between the ages of 18 65 years old. Patients must be able to give informed consent prior to and again after transplantation Lung transplant patients unable to give informed consent. Prior adverse reaction to the drug itraconazole or voriconazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Fungal infection prophylaxis</keyword>
	<keyword>Lung transplant</keyword>
	<keyword>Fungal infection post lung transplant</keyword>
</DOC>